RE:RE:RE:FD is spot on....It won't happen in a short term period, but..... ------------------ If PBI-4050 reach the market in all indications, as Esbriet Worth about $8.3B for IPF, on top of that you can add a bigger amount for the renal applications, which is aby far a bigger market. Also, plasminogen, AAT, IVIG, 2 other orphan indications to come, we might end up with a company with a really interesting portfolio. I can't predict or say all of this will happen, but the potential in 5 years from now is huge. I have no problem to see $10 in 3-4 years.